MEDTRONIC'S BRADYCARDIA PACERS HELP PUSH SECOND QUARTER SALES TO $408.2 MIL.
This article was originally published in The Gray Sheet
Executive Summary
MEDTRONIC'S BRADYCARDIA PACERS HELP PUSH SECOND QUARTER SALES TO $408.2 MIL., a 22.9% gain for the quarter (ended Oct. 28) over the same period a year ago. Bradycardia unit sales were higher than during "any quarter in the company's history," the firm said, adding that pacemaker results were aided by the performance of the Thera line and model 9790 programmer in European markets. The Thera devices were commercially released on Nov. 1 in Japan and Canada and are under study in the U.S.